Atea Pharmaceuticals quadruples headcount, fueled by Roche joint venture

Atea pulled in $60.4 million in revenue in the second quarter, mostly attributable to a $50 million milestone payment from Roche for positive results from a Covid-19 antiviral the two are jointly developing. Atea says its antiviral pill causes a "rapid decline in viral load," limiting the replication of SARS-CoV-2 in the lungs and potentially offering another tool with which to battle the pandemic.